EctoLife is not a real facility. It is a concept video created by science communicator and filmmaker Hashem Al-Ghaili, depicting a futuristic building filled with rows of transparent pods growing human babies from embryo to full term. The video went viral in December 2022, and a linguistic analysis of over 15,000 YouTube comments found that many viewers genuinely believed they were watching a news report about an existing technology.1Medical Humanities. Role of science fiction in conceptualising the reproductive future: a linguistic and literary perspective Real artificial womb research does exist and has reached genuinely impressive milestones in animal models, but the gap between what has been achieved in a laboratory and what EctoLife imagines is vast enough to deserve a careful look.
The Video That Fooled Viewers
The EctoLife video was slickly produced, complete with a narrator describing features like genetic customization, real-time health monitoring, and app-controlled growth environments. It looked and sounded like a corporate product launch. No disclaimer flagged it as speculative fiction, and because it landed at a time of rapid advances in reproductive technology and AI, many people took it at face value. Researchers who later analyzed the public response found a rich mix of reactions in the comment section: fascination, horror, religious objection, feminist critique, and plenty of confusion about whether the facility was actually under construction. The video became a kind of Rorschach test for how people feel about decoupling pregnancy from the human body. But the technology it described, growing a human being entirely outside a womb from the moment of conception, does not exist and is not close to existing.
What Real Artificial Womb Research Has Achieved
The most advanced work in this area involves supporting extremely premature lambs, not growing organisms from scratch. The best-known system is the Biobag, developed at the Children’s Hospital of Philadelphia (CHOP). In a landmark 2017 study, researchers showed that fetal lambs at a developmental stage equivalent to a roughly 23-week human infant could be kept alive and growing in a fluid-filled bag connected to an oxygenator for up to four weeks. The lambs maintained stable blood flow, normal oxygen levels, and continued to develop their lungs, brains, and bodies at rates comparable to what would happen inside the mother.2Nature Communications. An extra-uterine system to physiologically support the extreme premature lamb A related study optimizing the way the system connected to the lamb’s blood vessels confirmed that using the umbilical artery and vein, rather than other cannulation routes, delivered the most reliable and longest-lasting support runs.3PubMed Central. Umbilical cannulation optimizes circuit flows in premature lambs supported by the EXTra-uterine Environment for Neonatal Development (EXTEND)
A separate program in Australia and Japan, known as the EVE (ex vivo uterine environment) system, has taken a parallel approach. Early iterations kept premature lambs alive for about 18 hours on average, but by adding a second oxygenator to reduce circuit resistance and refining infection control, the team eventually achieved survival of up to one week in most of their test subjects without infection.4PubMed Central. Development of an artificial placenta for support of premature infants: narrative review of the history, recent milestones, and future innovation In a later trial, seven of eight extremely preterm lamb fetuses supported by the EVE system completed five full days of therapy with weight, brain size, and lung weight all comparable to controls that had developed naturally.5PubMed. Successful use of an artificial placenta to support extremely preterm ovine fetuses at the border of viability
These results are genuinely remarkable. But they involve lambs, not humans, and they involve sustaining an already-developing fetus for days or weeks, not growing one from an embryo. The CHOP system’s goal has always been to serve as a bridge therapy for babies born so early that their lungs cannot handle air and conventional incubators offer bleak odds. Nobody involved in this research is building a pod farm.
Why a Pumpless Design Matters
One of the key engineering insights in modern artificial womb work is avoiding the use of a mechanical pump to push blood through the circuit. In a fetus, the heart does the pumping. The placenta has extremely low resistance, allowing the fetal heart to drive blood through it without help. If you replace the placenta with an artificial oxygenator and force blood through it with a mechanical pump, you risk damaging blood cells, disrupting the delicate fetal circulatory patterns, and triggering inflammation. Early artificial placenta prototypes in the University of Michigan program demonstrated that a pumpless setup, where the fetal heart alone drove blood through a low-resistance oxygenator, could maintain normal-looking fetal circulation. Ductal blood flow, a hallmark of fetal cardiovascular physiology, persisted at roughly 84% of baseline during pumpless support.6PubMed Central. Development of an artificial placenta I: pumpless arterio-venous extracorporeal life support in a neonatal sheep model The EVE team found that in their pumpless setup, circuit blood flow tracked closely with the lamb’s own blood pressure, reinforcing the idea that letting the fetal heart run the show produces more physiological results.7Pediatric Research. Novel modification of an artificial placenta: pumpless arteriovenous extracorporeal life support in a premature lamb model
Getting this right has been central to every serious artificial womb program. The oxygenator needs to have low enough resistance that a tiny fetal heart can push adequate blood through it without exhausting itself, and it needs to exchange gases efficiently enough that oxygen delivery stays in a normal range. Building devices that meet both criteria at the scale of a human fetus remains one of the hardest unsolved problems in the field. A study on microfluidic artificial lung technology found that combining a specialized surface coating with nitric oxide in the gas supply improved device biocompatibility in animal models, but the researchers noted that neither approach alone reached significance in their sample size.8PubMed Central. Assessing and improving the biocompatibility of microfluidic artificial lungs In short, the devices that work for lamb-sized blood vessels and flow rates still need substantial redesign before they could function safely for a human fetus.
The Long List of Unsolved Problems
Even for the more modest goal of keeping a very premature human baby alive for a few extra weeks, the translational barriers are daunting. A 2025 narrative review cataloged the major hurdles standing between successful lamb experiments and a human clinical trial:9PubMed Central. Artificial Placenta and Partial Ectogenesis for Extremely Preterm Infants: A Narrative Review
- Vascular access: Reliably connecting to the tiny, fragile umbilical vessels of a 22- to 24-week human infant without clotting or damage.
- Oxygenator design: Building devices with low enough resistance to work at fetal flow rates and pressures, which are much lower than in adult life-support circuits.
- Blood compatibility: Preventing clotting in the circuit without using anticoagulants at doses that could cause bleeding in a fragile fetus.
- Infection control: Maintaining a sterile or near-sterile fluid environment around the fetus for weeks at a time, when any contamination of the amniotic fluid could be catastrophic.
- Placental endocrine function: The human placenta is not just a gas-exchange organ. It produces hormones, growth factors, and metabolic signals that guide organ maturation. No current system replicates this.
That last point is worth lingering on. The EctoLife video imagined a machine that handled everything: nutrition, oxygenation, waste removal, hormonal signaling, even a soundtrack of the mother’s heartbeat piped in for emotional development. In reality, we do not fully understand all of what the placenta does, let alone know how to replicate it. The placenta secretes hormones that regulate fetal growth, immune tolerance, brain development, and the timing of organ maturation. Replacing it with a machine would require solving problems in endocrinology, immunology, and developmental biology simultaneously, many of which are still active research frontiers.
Synthetic Amniotic Fluid and the Lung Problem
One area where there has been tangible progress is in understanding what the fluid surrounding the fetus should look like. In a natural pregnancy, amniotic fluid bathes the fetal lungs and gut, playing a role in tissue maturation. A 2025 rodent study tested a synthetic amniotic fluid formulation against standard medical fluids like normal saline and lactated Ringer’s solution. The synthetic version reduced lung inflammation and improved the expression of key surfactant proteins compared to both conventional fluids, with minimal effects on the gastrointestinal tract.10PubMed Central. In Vivo Effect of a Synthetic Amniotic Fluid on Fetal Lung and Gastrointestinal Tract: A Pre-Clinical Rodent Model Surfactant is the substance that keeps the tiny air sacs in the lungs from collapsing, and premature babies are famously short on it. Getting the fluid composition right could be important for any future human application, since the lungs of a 23-week fetus are still in an early stage of development and respond differently to their chemical environment than mature lungs do.
Interestingly, the CHOP team’s lamb experiments showed that lung tissue in their Biobag progressed through a full developmental stage, moving from an earlier structural phase to a more mature one, without the use of steroids or other interventions commonly given to premature infants today. By the end of their support period, the lambs’ lung function, tested by mechanical ventilation, matched that of lambs born at the same gestational age from natural pregnancies.11European Journal of Obstetrics & Gynecology and Reproductive Biology: X. Artificial womb technology – A more physiologic solution to treating extreme prematurity That is encouraging, but again, these are lambs whose pregnancies were already well underway before being transferred to the device.
Partial Ectogenesis vs. the Full Science Fiction Version
This distinction keeps coming up because it is the crux of the gap between reality and the EctoLife concept. What researchers are working toward is partial ectogenesis: taking a fetus that has already developed substantially inside a human uterus and sustaining it artificially for the final weeks before it can survive in the outside world. The target population is babies born at the very edge of viability, around 22 to 24 weeks, where survival rates are low and disability rates are high even with the best neonatal care available.
What EctoLife depicted is complete ectogenesis: fertilization, embryo implantation, and the entire nine months of development happening outside a human body. Complete ectogenesis would require solving every problem that partial ectogenesis faces, plus the far harder challenge of sustaining an embryo through its earliest and most fragile stages. Before about 20 weeks, the fetus is too small for any existing cannulation technique, its vessels too delicate, its oxygen demands met by diffusion across the placental barrier in ways we cannot yet mimic artificially. We do not have an artificial version of the endometrium that could accept an implanting embryo, nor a way to provide the complex hormonal cascade that governs the first trimester. The science fiction version requires breakthroughs in at least a dozen fields that have not yet occurred.
What an Artificial Womb Would Mean for the Law
Even the partial version raises legal questions that existing frameworks are not ready for. In many jurisdictions, abortion law is built around the concept of viability: the point at which a fetus can survive outside the womb. If artificial womb technology pushes that point earlier, the legal landscape shifts. A legal analysis in the Michigan Journal of Gender and Law argued that the artificial womb is a genuine threat to current viability-based frameworks and that its arrival is far from far-fetched.12Michigan Journal of Gender & Law. How Viable is Viability? Artificial Womb Technology and the Threat to Abortion Access
In England and Wales, the situation is slightly different. An analysis in the Journal of Law and the Biosciences found that under the Abortion Act 1967, the introduction of artificial womb technology would not automatically change who qualifies for a legal termination, because the law does not require a pregnant person to choose any particular method of ending a pregnancy. However, the same paper noted that the concept of a fetus being “capable of being born alive,” which is central to the Infant Life (Preservation) Act, is already described as inconsistent in case law and “an ever-changing concept often dependent on the technology available.”13Journal of Law and the Biosciences. Abortion & ‘artificial wombs’: would ‘artificial womb’ technology legally empower non-gestating genetic progenitors to participate in decisions about how to terminate pregnancy in England and Wales? A technology that could sustain a 20-week fetus would blow a hole in that already-unstable legal boundary.
Beyond abortion, artificial womb technology would force a rethinking of parentage law. The ancient legal principle of mater semper certa est — the mother is always certain — assumes a gestational mother exists. If a child develops entirely in an artificial womb, that assumption collapses. A study examining artificial womb technology in the context of European Union family law argued that profound legal reforms would be necessary, creating a new category of parentage in which only genetic or social parents exist, with no gestational mother at all.14Teisės apžvalga. Surrogacy versus artificial womb technology: the future of reproduction in the European Union A separate bioethics paper raised the concern that ectogenesis, even when pursued for good reasons like reducing unintended pregnancies, threatens to disrupt the connection between biological procreation and the responsibilities that come with parenthood.15Journal of Medical Ethics. Willing mothers: ectogenesis and the role of gestational motherhood
Who Would Have Access
If artificial womb technology eventually reaches clinical use, even in the limited form of a bridge device for extremely premature infants, the question of cost and access will be immediate. A public health analysis flagged the risk that commercialization of artificial wombs could deepen existing inequalities, since the high costs of setting up and maintaining such facilities would likely put them out of reach for marginalized populations.16PubMed Central. Artificial womb: opportunities and challenges for public health Neonatal intensive care is already among the most expensive forms of medical treatment in the world, and an artificial womb system would add layers of specialized equipment, sterile fluid management, around-the-clock monitoring, and expertise that few hospitals could provide.
The EctoLife video, with its sleek consumer-product aesthetic and talk of genetic customization packages, fed directly into this concern. It presented artificial gestation as a luxury service rather than a medical intervention, complete with overtones of designer babies and premium add-ons. For researchers actually working in this space, that framing is a headache. Their goal is to save babies who are dying at 22 weeks, not to build a boutique reproduction service for the wealthy. But the EctoLife concept video has become a reference point in public discourse, and the fears it activated about commodification and access are not unreasonable even if the specific product it depicted is fiction.
The Microbiome and Immune Development Problem
One of the subtler challenges with any form of prolonged artificial gestation involves the microbial world. In a natural pregnancy, the fetus is exposed to maternal microbes in ways that are thought to prime its developing immune system. A baby born vaginally picks up an additional load of bacteria from the birth canal that begins colonizing the gut and skin almost immediately. A baby that develops entirely in a sterile artificial environment would miss all of that.
A review of the microbiome implications of artificial womb design raised the possibility that beneficial bacterial communities could be deliberately introduced into the artificial environment using probiotics, potentially helping to calibrate the fetal immune system. But the same authors acknowledged that fundamental questions about which strains, what doses, and how long to administer them remain unanswered.17Journal of Reproductive Immunology. A critical review of the recent concept of artificial mechanical uterus design in relation to the maternal microbiome: An Update to past researches And there is another layer to this: in utero, the fetal liver handles drug and chemical metabolism differently from an adult liver. Conjugation enzymes that process and clear certain compounds are limited in the fetus, meaning that metabolites can accumulate in ways they would not in an adult body. Studies of fetal sheep have confirmed that fetal hepatic drug elimination is real but operates through different enzyme pathways, with sulfation more active than the glucuronidation that dominates in adults.18Pharmacology & Therapeutics. Fetal hepatic drug elimination Any artificial womb system that introduces substances into the fetal environment, whether medications, nutrients, or probiotics, would need to account for this immature metabolic machinery, adding yet another variable to an already complex engineering challenge.